Candel Therapeutics (CADL) Capital Expenditures (2020 - 2025)

Candel Therapeutics has disclosed Capital Expenditures across 6 years of filings, most recently posting -$46000.0 for Q4 2025.

• Capital Expenditures for Q4 2025 came in at -$46000.0, down 453.85% year-over-year; the trailing twelve-month figure through Dec 2025 was $132000.0 (up 725.0% YoY), and the FY2025 annual result was $132000.0, up 725.0% from the prior year.
• Capital Expenditures came in at -$46000.0 for Q4 2025 at Candel Therapeutics, down from $165000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.8 million in Q1 2021 to a low of -$911000.0 in Q2 2021.
• The 5-year median for Capital Expenditures is $31500.0 (2023), against an average of $125450.0.
• Peak annual rise in Capital Expenditures reached 1750.0% in 2025, while the deepest fall reached 453.85% in 2025.
• Candel Therapeutics' Capital Expenditures stood at $504000.0 in 2021, then slumped by 138.1% to -$192000.0 in 2022, then jumped by 124.48% to $47000.0 in 2023, then sank by 72.34% to $13000.0 in 2024, then tumbled by 453.85% to -$46000.0 in 2025.
• The last three Capital Expenditures figures came in at -$46000.0 (Q4 2025), $165000.0 (Q3 2025), and -$3000.0 (Q2 2025), per Business Quant data.